Participants assigned to a lifestyle intervention program or metformin treatment designed to help prevent or delay type 2 diabetes onset attained well-being scores of 6.81 and 6.69, respectively, compared with only 6.67 in those who had placebo treatment, a study in Diabetes Care revealed. Researchers also found that lifestyle intervention and metformin treatment resulted in higher cumulative direct medical costs, but showed greater efficacy than placebo therapy.
Study backs efficacy, cost-effectiveness of diabetes prevention efforts
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||